7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation

References

• Gallo RC, Whang-Peng J, Adamson RH. (1971). Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst, 46:789–795.
   PubMed Web of Science ®Google Scholar
• Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest, 101:847–854.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res, 7:2182–2194.
   PubMed Web of Science ®Google Scholar
• Kaneda N, Nagata H, Furuta T, Yokokura T. (1990). Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res, 50:1715–1720.
   PubMed Web of Science ®Google Scholar
• Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, Redinbo MR. (2002). Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol, 9:337–342.
   PubMedGoogle Scholar
• Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343:905–914.
   PubMed Web of Science ®Google Scholar
• Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N et al.; CPT-11 Lung Cancer Study Group West. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer, 88:335–341.
   PubMed Web of Science ®Google Scholar
• Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ et al. (2003). Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol, 21:291–297.
   PubMed Web of Science ®Google Scholar
• Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF. (2004). Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos, 32:505–511.
   PubMed Web of Science ®Google Scholar
• Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S et al. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm, 270:93–107.
   PubMed Web of Science ®Google Scholar
• Lu Z, Cui TL, Wen FL, Jin, GC, Xin QT, Ying ZZ, Xing L, Hai FL, Xiao KL. (2012). Physical characterization and cellular uptake of propylene glycol liposomes in vitro. Drug Dev Ind Pharm, 37(9):1110–1118.
   Google Scholar
• Sumio C, Hirokazu S, Kohei T, Kazuhiro, M. (2011) Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev Ind Pharm, 37(4):367–372.
   PubMed Web of Science ®Google Scholar
• Mohammed MM, Hoda AE, Magda WS. (2010). Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.
   Google Scholar
• N.Başaran M, Zelihagül D, Şükran Y, Dinç E, Ahmet N. (2011). New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations. Drug Dev Ind Pharm, 37(7):775–789.
   PubMed Web of Science ®Google Scholar
• Praveen KG, Shikha M, Vipin BG, Mahendra SR, Suresh P, Bhavin AS. (2010). Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Dev Ind Pharm, 36(6):638–646.
   PubMed Web of Science ®Google Scholar
• Xin YL, Song H, Yi J, Li YQ. (2012). Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm, 38(3):314–322.
   PubMed Web of Science ®Google Scholar
• Wen JC, Qing FL, Xi C, Rong G, Juan L, Yi MW, Guo AL. (2010). Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm 36(10):1186–1194.
   PubMed Web of Science ®Google Scholar
• Langer R. (1998). Drug delivery and targeting. Nature, 392:5–10.
   PubMed Web of Science ®Google Scholar
• Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. (1985). Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta, 817:67–74.
   PubMed Web of Science ®Google Scholar
• O’Brien DF, Klingbiel RT, Specht DP, Tyminski PN. (1985). Preparation and characterization of polymerized liposomes. Ann N Y Acad Sci, 446:282–295.
   PubMed Web of Science ®Google Scholar
• Sohail A, Shalini K, Musarrat HW, Mohammed A, Mohammad ZA, Iqbal A, Sushma T, Zeenat IK, Roop KK, Farhan JA. (2012). Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. Drug Dev Ind Pharm, 38(1), 84–92.
   PubMed Web of Science ®Google Scholar
• Mohammed SE, Ahmed A, Essam AN, Rawia MK, Dina MM, Ahmed IE, Sameh HAE. (2011). Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev Ind Pharm, 37(9):1110–1118.
   PubMed Web of Science ®Google Scholar
• Mohammed SE, Ahmed A, Tamer E, Rania MAE, Ahmed AAK. (2011). Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm, 37(9):1110–1118.
   PubMed Web of Science ®Google Scholar
• Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. (1986). Proliposomes: a novel solution to an old problem. J Pharm Sci, 75:325–329.
   PubMed Web of Science ®Google Scholar
• Katare OP, Vyas SP, Dixit VK. (1991). Proliposomes of indomethacin for oral administration. J Microencapsul, 8:1–7.
   PubMed Web of Science ®Google Scholar
• Xiao YY, Song YM, Chen ZP, Ping QN. (2006). Preparation of silymarin proliposome: A new way to increase oral bioavailability of silymarin in beagle dogs.Int J Pharm, 319:162–168.
   PubMed Web of Science ®Google Scholar
• Xu H, He L, Nie S, Guan J, Zhang X, Yang X et al. (2009). Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release, 140:61–68.
   PubMed Web of Science ®Google Scholar
• Fei Xia, Daode Hua, Heyang Jin, Yaping Zhao, Jiamiao Liang. (2010). Preparation of lutein proliposomes by supercritical anti-solvent technique. J Food Hydrocolloids, 24:1–8.
   Web of Science ®Google Scholar
• Chopra S, Patil GV, Motwani SK. (2007). Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. Eur J Pharm Biopharm, 66:73–82.
   PubMed Web of Science ®Google Scholar
• Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK. (2007). Optimisation of polyherbal gels for vaginal drug delivery by Box–Behnken statistical design. Eur J Pharm Biopharm, 67:120–131.
   PubMed Web of Science ®Google Scholar
• Khan S, Ahmad A, Guo W, Wang YF, Abu-Qare A, Ahmad I. (2005). A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). J Pharm Biomed Anal, 37:135–142.
   PubMed Web of Science ®Google Scholar